GlassScriptPhysician profile
Clavis Registe
NPI 1205349123
$2,479.13
in general payments reported to CMS, 2019-2025
29 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $32.05 · 2023: $173 · 2024: $737 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $621.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $202.02 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $168.66 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $144.57 | 2021-2025 | |
| Corcept Therapeutics | $132.70 | 2024-2025 | Korlym |
| Amgen INC. | $111.80 | 2021-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $111.27 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $108.86 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $101.27 | 2024-2025 | Trelegy Ellipta |
| Abbott Laboratories | $94.86 | 2023-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.56 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $84.43 | 2021-2025 | |
| Esperion Therapeutics, INC. | $67.91 | 2021 | |
| Abiomed | $59.71 | 2025 | |
| Janssen Pharmaceuticals, INC | $55.31 | 2021-2025 | Spravato |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.07 | 2024-2025 | |
| Inspire Medical Systems, INC. | $40.24 | 2024 | Inspire |
| Dexcom, INC. | $27.70 | 2021 | |
| Madrigal Pharmaceuticals | $25.75 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $24.60 | 2021 | |
| Medtronic, INC. | $23.25 | 2025 | Venaseal |
| Viatris Specialty LLC | $21.54 | 2025 | Yupelri |
| Itamar Medical INC | $21.02 | 2023 | Watchpatone |
| Gilead Sciences, INC. | $17.92 | 2025 | |
| Edwards Lifesciences Corporation | $17.17 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biohaven Pharmaceuticals, INC. | $15.26 | 2021 | |
| Inari Medical, INC. | $13.53 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.33 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clavis Registe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.